DMC and Conagen enter into an agreement for commercial manufacturing of L-alanine
Type of post: NEWS IN BRIEF.
DMC Biotechnologies and Conagen have entered into a manufacturing agreement for the commercial production of DMC’s first product, L-alanine.
Press release: “DMC and Conagen Partner for Commercial Manufacturing of L-alanine”, 22/04/2021.
Related posts:
- “DMC demonstrates full commercial scale production of L-alanine”, 16/03/2021.
Figure 1. L-alanine
This partnership combines Conagen’s production expertise with DMC’s bioprocess technology and follows demonstration of commercial-scale production in March 2021. L-alanine is a naturally occurring amino acid used widely in homecare products, human nutrition, and pharmaceutical applications. DMC’s fermentation technology enables L-alanine to be produced with attractive economics as part of a regional supply chain with increased reliability and greater sustainability. DMC has a robust product pipeline, including additional amino acids, that will subsequently be brought to the market.
